Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Salvador Cabrera Figueroa"'
Autor:
Elena López Aspiroz, Gloria Liliana Porras Hurtado, Angel Carracedo, Aurelio Fuertes Martín, Salvador Cabrera Figueroa, Raquel Cruz, Alfonso Domínguez-Gil Hurlé
Publikováno v:
Personalized medicine. 11(3)
Aims: We present a genetic association study in 106 European HIV-infected individuals aimed at identifying and confirming polymorphisms that have a significant influence on toxicity derived from treatment with lopinavir/ritonavir (LPV/r). Patients &
Autor:
Alfonso Domínguez-Gil Hurlé, María Jesús Hernández Arroyo, María Paz Valverde Merino, Salvador Cabrera Figueroa
Publikováno v:
Personalized medicine. 13(2)
The pharmacological treatment of HIV is complex and varies considerably among patients, as does the response of patients to therapy, requiring treatment plans that are closely tailored to individual needs. Pharmacists can take an active role in indiv
Autor:
María Paz Valverde Merino, Alicia Iglesias Gómez, Salvador Cabrera Figueroa, Alfonso Domínguez-Gil Hurlé, Elena López Aspiroz
Publikováno v:
Clinical Drug Investigation. 35:61-66
Cytochrome P450 (CYP) 3A4 has been considered to be the most important enzyme system for metabolism of lopinavir/ritonavir (LPV/r), a widely used HIV protease inhibitor (PI) recommended during pregnancy. Herein we present a clinical case of a pregnan
Autor:
María Paz Valverde Merino, Elena López Aspiroz, Salvador Cabrera Figueroa, Angel Carracedo, Miguel Cordero Sánchez, Dolores Santos Buelga, María José García Sánchez, Alfonso Domínguez-Gil Hurlé
Publikováno v:
Personalized Medicine. 11:693-704
Aim: This study aims to develop a population pharmacokinetic/pharmacogenetic model for lopinavir/ritonavir (LPV/r) in European HIV-infected patients. Materials & methods: A total of 693 LPV/r plasma concentrations were assessed and 15 single-nucleoti
Autor:
Raquel Cruz Guerrero, Liliana Porras Hurtado, Alfonso Domínguez-Gil Hurlé, Ángel Carracedo Álvarez, Almudena Sánchez Martín, Salvador Cabrera Figueroa
Publikováno v:
Pharmacogenomics. 14:1167-1178
Aim: This article evaluates which genetic factors are involved in CNS toxicity related to long-term treatment with efavirenz (EFV) standard doses and their relationship with plasma concentrations. Patients & methods: A total of 119 HIV-positive patie
Autor:
Esteban Ribera Pascuet, Salvador Cabrera Figueroa, Dolores Santos Buelga, María José García Sánchez, Alfonso Domínguez-Gil Hurlé, Rosa María López Galera, Elena López Aspiroz
Publikováno v:
Therapeutic Drug Monitoring. 33:573-582
Background A relationship between plasma concentrations and viral suppression in patients receiving lopinavir (LPV)/ritonavir (RTV) has been observed. Therefore, it is important to increase our knowledge about factors that determine interpatient vari
Autor:
María Paz Valverde Merino, Miguel Cordero Sánchez, Almudena Sánchez Martín, Alicia Iglesias Gómez, Alfonso Domínguez-Gil Hurlé, Salvador Cabrera Figueroa
Publikováno v:
Clinical Drug Investigation. 30:405-411
A 48-year-old Caucasian male patient presented with severe adverse drug events (ADEs) while being treated with a standard dose (600 mg/day) of efavirenz. The patient's clinical course was favourable; however, he also described intense nightmares, cra
Autor:
Belén García-Berrocal, José Manuel González-Buitrago, Miguel Cordero Sánchez, Almudena Sánchez Martín, Maria Victoria Hernández, Carmen Bustos Tovar, María Paz Valverde Merino, María Isidoro-García, Aurelio Fuertes Martín, Salvador Cabrera Figueroa, Alicia Iglesias Gómez
Publikováno v:
Pharmacogenomics. 15(7)
Aim: Antiretroviral treatment implies a high cost to the healthcare system. The aim of this study was to evaluate the clinical and economic impact of efavirenz (EFV) dose adjustment by monitoring plasma concentrations and pharmacogenetic analysis of
Autor:
Aurelio, Fuertes, Aurelio Fuertes, Martín, Salvador, Cabrera, Salvador Cabrera, Figueroa, Maria de la Paz, Valverde, María de la Paz Valverde, Merino, Alfonso, Domínguez-Gil, Alfonso Domínguez-Gil, Hurléé
Publikováno v:
AIDS Patient Care and STDs. 23:143-145
Hyperhidrosis may be an adverse drug event (ADE) induced by the effect on any of the components of human thermoregulation. Some of our efavirenz (EFV)-treated patients have reported excessive nocturnal sweating that resolved after dose reduction. A r
Autor:
Rosa Sepúlveda Correa, Salvador Cabrera Figueroa, María José García Sánchez, Lorena Hernández García, Carmen Bustos Bernal, Alfonso Domínguez-Gil Hurlé, María del Mar Fernández de Gatta
Publikováno v:
Therapeutic drug monitoring. 32(5)
The aim of this study was to show the benefits of combining therapeutic drug monitoring (TDM) and pharmacogenetic analyses to optimize efavirenz (EFV) therapy. Patients were selected to minimize nongenetic differences between patients: 32 HIV adheren